Liquidia (LQDA) Insider Arthur Kirsch Buys 5,882 Shares

Arthur Kirsch, a notable insider, bought 5,882 shares of Liquidia Corporation on June 16, 2026. The shares were trading around $69.02 at the time of the transaction. This purchase was not made under a pre-planned trading scheme, indicating a direct interest in increasing his stake in the company.

Insider Buying and Selling at Liquidia Corporation

In addition to Arthur Kirsch, several other insiders including Stephen Bloch, Katherine Rielly-Gauvin, Paul Manning, Joanna Horobin, and Damian DeGoa also bought 5,882 shares each on the same day. None of these transactions were part of a planned trading program, suggesting a coordinated confidence in Liquidia's prospects.

Other Institutional Activity in Liquidia Corporation

Farallon Capital Management LLC held its position steady with 8,656,038 shares valued at approximately $326.7 million. Caligan Partners LP also maintained its holding at 8,118,892 shares worth about $306.4 million. BlackRock, Inc. added 781 shares, bringing its total to 5,489,144 shares valued at $207.2 million. Findell Capital Management LLC significantly increased its stake by 650,663 shares, ending with 3,502,112 shares valued at $132.2 million. Vanguard Capital Management LLC established a new position with 2,926,945 shares worth about $110.5 million.

Liquidia Corporation Stock Up 98.4%

Shares of NasdaqCM:LQDA traded near $69.02. Liquidia Corporation, with a market cap of around $6.1 billion, has a P/E ratio of 403.82 and a forward P/E of 12.32. The stock's 52-week range is between $11.85 and $73.22. The 50-day moving average is $51.34, while the 200-day moving average stands at $36.69. Liquidia's current ratio is 2.22, with a quick ratio of 1.98 and a debt-to-equity ratio of 170.22.

Recent Earnings

For its recent quarter, Liquidia reported revenue of approximately $288.1 million, reflecting a growth of 41.6%. The company achieved a net margin of 7.74% and a return on equity of 28.18%. Earnings per share stood at $0.17. The next earnings report is expected on August 12, 2026.

Analysts Set New Price Targets

On June 5, 2026, HC Wainwright & Co. maintained its buy rating for Liquidia with a price target of $75.0. Previously, on May 12, Wells Fargo reaffirmed its buy rating with a target of $62.0, and Needham set a target of $70.0. The consensus among eight analysts is a strong buy, with a target mean price of $66.13.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, North Carolina. It focuses on developing and commercializing products for rare cardiopulmonary diseases. Its leading product, YUTREPIA, is an inhaled dry powder formulation for treating pulmonary arterial hypertension. The company also offers Remodulin, a treprostinil injection, and is developing L606, a liposomal formulation for similar conditions. Liquidia employs about 216 people and is led by CEO Dr. Roger A. Jeffs.

Bottom Line

Arthur Kirsch's recent purchase of Liquidia shares highlights insider confidence in the company's prospects. Liquidia's strong market position and recent earnings growth are attracting attention from both insiders and institutional investors. With a strong buy consensus from analysts, the company continues to be a focal point in the healthcare sector. Remember, this insider activity reflects past decisions and may not indicate future performance.